Strategic planning for patients who present with metastatic colorectal cancer

Al B. Benson*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


The current array of viable therapeutic options for metastatic colorectal cancer allows clinicians to strategically plan for the care of patients over a longer period than ever before. The availability of proven agents such as irinotecan, oxaliplatin, capecitabine, bevacizumab, and cetuximab has resulted in several new combination regimens that can be administered over the course of multiple lines of therapy, including, for the first time, a fourth line of therapy. For most patients with good performance status, a treatment continuum of cytotoxic and targeted agents over multiple therapeutic lines offers more than palliation, and it can prolong disease-free survival and overall survival.

Original languageEnglish (US)
Pages (from-to)18-25
Number of pages8
JournalCommunity Oncology
Issue number6 SUPPL. 2
StatePublished - Jun 1 2006

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Strategic planning for patients who present with metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this